CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CCTG is excited to be hosting the new Clinical Research Associate (CRA) lunch and learn training program. This program is intended to provide CRAs with practical information and training around the activation and conduct of CCTG studies.
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs
The HN13 clinical trial has recently opened in Canada and will explore a new radiotherapy technique called stereotactic body radiotherapy (SBRT) to treat patients with advanced head and neck cancer. Researchers want to know if SBRT offers better cancer and symptom control than the standard radiotherapy (RT).
PM2 CAN-IMPACT-IO is a unique national initiative to measure, predict and assess cancer treatment outcomes in patients who have been treated with immunotherapy.
Patients on CCTG clinical trials who consent to CAN-IMPACT-IO will have blood and tumour tissue biopsy taken to analyses to look for features that correlate with benefit or lack of benefit to immunotherapy.
CCTG welcomes new Patient Representative Sally Nystrom who will be supporting the CCTG Melanoma Committee
The 2024 EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics was held last week in Barcelona and CCTG was there with two IND poster presentations. The ENA symposium is a leading event for drug development and translational research. It focuses on preclinical, and phase I studies and provides a platform for scientific discussions on the latest advancements in targets and therapeutics.
